Skip to main content
. Author manuscript; available in PMC: 2022 Nov 2.
Published in final edited form as: Clin Cancer Res. 2022 May 2;28(9):1979–1990. doi: 10.1158/1078-0432.CCR-20-0468

Figure 5.

Figure 5.

Effects of onalespib (0.4μM) in an ex-vivo patient-derived organotypic slice culture model (A) Changes in gene expression upon treatment of a human glioma slice culture specimen (GBM149) with onalespib as determined by RNA-Seq analysis. (B) Immunoblot analysis of levels of DNA-repair proteins, ATM, CHK1, and RAD51 in human glioma slice culture specimens (GBM136, OLIG137 and GBM142) upon treatment with onalespib. GAPDH was assayed as a loading control.(C) Immunohistochemical assessment of tissue levels of EGFR, p-S6 and γH2AX in a patient-derived tumor slice specimen (GBM182). (D) Immunoblot analysis of human tumor tissue exposed to onalespib or DMSO for levels of HSP90, HSP70, AKT, p-AKT, ERK, p-ERK, S6, p-S6, GAPDH (as loading control) levels.